Metrochem API Private Limited Metrochem API Private Limited

X
[{"orgOrder":0,"company":"Spiral Therapeutics","sponsor":"Savoir Capital","pharmaFlowCategory":"D","amount":"$8.2 million","upfrontCash":"Undisclosed","newsHeadline":"Spiral Therapeutics Completes $8.25M Financing and Initiates Phase 2 Trial in Meniere's Disease","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I"}]

Find Clinical Drug Pipeline Developments & Deals by Spiral Therapeutics

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            SPT-2101 is a sustained-release steroid formulation designed for precise inner ear administration using Spiral's novel delivery procedure. Spiral recently completed enrollment of an open label pilot clinical study of SPT-2101 in 10 patients with Meniere's disease.

            Lead Product(s): SPT-2101

            Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: SPT-2101

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Savoir Capital

            Deal Size: $8.2 million Upfront Cash: Undisclosed

            Deal Type: Financing January 10, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY